Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Genome-wide assessment of antimicrobial tolerance in Yersinia pseudotuberculosis under ciprofloxacin stress.

Willcocks S, Huse KK, Stabler R, Oyston PCF, Scott A, Atkins HS, Wren BW.

Microb Genom. 2019 Nov;5(11). doi: 10.1099/mgen.0.000304.

2.

A structural and biochemical comparison of Ribonuclease E homologues from pathogenic bacteria highlights species-specific properties.

Mardle CE, Shakespeare TJ, Butt LE, Goddard LR, Gowers DM, Atkins HS, Vincent HA, Callaghan AJ.

Sci Rep. 2019 May 28;9(1):7952. doi: 10.1038/s41598-019-44385-y.

3.

The Fluoroquinolone Finafloxacin Protects BALB/c Mice Against an Intranasal Infection With Francisella tularensis Strain SchuS4.

Barnes KB, Hamblin KA, Richards MI, Laws TR, Vente A, Atkins HS, Harding SV.

Front Microbiol. 2019 May 1;10:904. doi: 10.3389/fmicb.2019.00904. eCollection 2019.

4.

Disulfiram, an alcohol dependence therapy, can inhibit the in vitro growth of Francisella tularensis.

Hamblin KA, Flick-Smith H, Barnes KB, Pereira-Leal JB, Surkont J, Hampson R, Atkins HS, Harding SV.

Int J Antimicrob Agents. 2019 Jul;54(1):85-88. doi: 10.1016/j.ijantimicag.2019.04.002. Epub 2019 Apr 25.

5.

Global Analysis of Genes Essential for Francisella tularensis Schu S4 Growth In Vitro and for Fitness during Competitive Infection of Fischer 344 Rats.

Ireland PM, Bullifent HL, Senior NJ, Southern SJ, Yang ZR, Ireland RE, Nelson M, Atkins HS, Titball RW, Scott AE.

J Bacteriol. 2019 Mar 13;201(7). pii: e00630-18. doi: 10.1128/JB.00630-18. Print 2019 Apr 1.

6.

High-throughput analysis of Yersinia pseudotuberculosis gene essentiality in optimised in vitro conditions, and implications for the speciation of Yersinia pestis.

Willcocks SJ, Stabler RA, Atkins HS, Oyston PF, Wren BW.

BMC Microbiol. 2018 May 31;18(1):46. doi: 10.1186/s12866-018-1189-5.

7.

Mitogen-activated protein kinases (MAPKs) are modulated during in vitro and in vivo infection with the intracellular bacterium Burkholderia pseudomallei.

D'Elia RV, Saint RJ, Newstead SL, Clark GC, Atkins HS.

Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2147-2154. doi: 10.1007/s10096-017-3038-0. Epub 2017 Aug 30.

8.

An integrated computational-experimental approach reveals Yersinia pestis genes essential across a narrow or a broad range of environmental conditions.

Senior NJ, Sasidharan K, Saint RJ, Scott AE, Sarkar-Tyson M, Ireland PM, Bullifent HL, Rong Yang Z, Moore K, Oyston PCF, Atkins TP, Atkins HS, Soyer OS, Titball RW.

BMC Microbiol. 2017 Jul 21;17(1):163. doi: 10.1186/s12866-017-1073-8.

9.

Demonstrating the Protective Efficacy of the Novel Fluoroquinolone Finafloxacin against an Inhalational Exposure to Burkholderia pseudomallei.

Barnes KB, Hamblin KA, Richards MI, Laws TR, Vente A, Atkins HS, Harding SV.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00082-17. doi: 10.1128/AAC.00082-17. Print 2017 Jul.

10.

Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague.

Hamblin KA, Armstrong SJ, Barnes KB, Davies C, Laws T, Blanchard JD, Harding SV, Atkins HS.

Front Microbiol. 2017 Feb 6;8:91. doi: 10.3389/fmicb.2017.00091. eCollection 2017.

11.
12.

A Bioluminescent Francisella tularensis SCHU S4 Strain Enables Noninvasive Tracking of Bacterial Dissemination and the Evaluation of Antibiotics in an Inhalational Mouse Model of Tularemia.

Hall CA, Flick-Smith HC, Harding SV, Atkins HS, Titball RW.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7206-7215. Print 2016 Dec.

13.

Bacillus anthracis TIR Domain-Containing Protein Localises to Cellular Microtubule Structures and Induces Autophagy.

Carlsson E, Thwaite JE, Jenner DC, Spear AM, Flick-Smith H, Atkins HS, Byrne B, Ding JL.

PLoS One. 2016 Jul 8;11(7):e0158575. doi: 10.1371/journal.pone.0158575. eCollection 2016.

14.

Intracellular replication of the well-armed pathogen Burkholderia pseudomallei.

Willcocks SJ, Denman CC, Atkins HS, Wren BW.

Curr Opin Microbiol. 2016 Feb;29:94-103. doi: 10.1016/j.mib.2015.11.007. Epub 2016 Jan 22. Review.

15.

Characterization of New Virulence Factors Involved in the Intracellular Growth and Survival of Burkholderia pseudomallei.

Moule MG, Spink N, Willcocks S, Lim J, Guerra-Assunção JA, Cia F, Champion OL, Senior NJ, Atkins HS, Clark T, Bancroft GJ, Cuccui J, Wren BW.

Infect Immun. 2015 Dec 28;84(3):701-10. doi: 10.1128/IAI.01102-15.

16.

Burkholderia pseudomallei kynB plays a role in AQ production, biofilm formation, bacterial swarming and persistence.

Butt A, Halliday N, Williams P, Atkins HS, Bancroft GJ, Titball RW.

Res Microbiol. 2016 Apr;167(3):159-67. doi: 10.1016/j.resmic.2015.11.002. Epub 2015 Nov 30.

PMID:
26654915
17.

The potential of liposome-encapsulated ciprofloxacin as a tularemia therapy.

Hamblin KA, Wong JP, Blanchard JD, Atkins HS.

Front Cell Infect Microbiol. 2014 Jun 18;4:79. doi: 10.3389/fcimb.2014.00079. eCollection 2014. Review.

18.

Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4.

Hamblin KA, Armstrong SJ, Barnes KB, Davies C, Wong JP, Blanchard JD, Harding SV, Simpson AJ, Atkins HS.

Antimicrob Agents Chemother. 2014 Jun;58(6):3053-9. doi: 10.1128/AAC.02555-13. Epub 2014 Mar 17.

19.

CpG oligonucleotides protect against Venezuelan equine encephalitis virus infection in a route-dependent manner.

Rees DG, Phillpotts RJ, Griffin KF, Lukaszewski RA, Laws TR, Atkins HS, Krieg AM, Titball RW.

Int J Antimicrob Agents. 2013 Dec;42(6):587-8. doi: 10.1016/j.ijantimicag.2013.09.001. Epub 2013 Oct 1. No abstract available.

PMID:
24210643
20.

The ability of CpG oligonucleotides to protect mice against Francisella tularensis live vaccine strain but not fully virulent F. tularensis subspecies holarctica is reflected in cell-based assays.

Rees DG, Hartley MG, Green M, Lukaszewski RA, Griffin KF, Atkins HS, Lyons R, Krieg AM, Titball RW.

Microb Pathog. 2013 Oct;63:16-8. doi: 10.1016/j.micpath.2013.04.013. Epub 2013 May 22.

PMID:
23707360
21.

Trimethoprim/sulfamethoxazole (co-trimoxazole) prophylaxis is effective against acute murine inhalational melioidosis and glanders.

Barnes KB, Steward J, Thwaite JE, Lever MS, Davies CH, Armstrong SJ, Laws TR, Roughley N, Harding SV, Atkins TP, Simpson AJ, Atkins HS.

Int J Antimicrob Agents. 2013 Jun;41(6):552-7. doi: 10.1016/j.ijantimicag.2013.02.007. Epub 2013 Mar 19.

PMID:
23517714
22.

Assessment of antimicrobial peptide LL-37 as a post-exposure therapy to protect against respiratory tularemia in mice.

Flick-Smith HC, Fox MA, Hamblin KA, Richards MI, Jenner DC, Laws TR, Phelps AL, Taylor C, Harding SV, Ulaeto DO, Atkins HS.

Peptides. 2013 May;43:96-101. doi: 10.1016/j.peptides.2013.02.024. Epub 2013 Mar 14.

PMID:
23500517
23.

Galleria mellonella as a model system to test the pharmacokinetics and efficacy of antibiotics against Burkholderia pseudomallei.

Thomas RJ, Hamblin KA, Armstrong SJ, Müller CM, Bokori-Brown M, Goldman S, Atkins HS, Titball RW.

Int J Antimicrob Agents. 2013 Apr;41(4):330-6. doi: 10.1016/j.ijantimicag.2012.12.009. Epub 2013 Feb 8.

PMID:
23402703
24.

Bacterial TIR-containing proteins and host innate immune system evasion.

Rana RR, Zhang M, Spear AM, Atkins HS, Byrne B.

Med Microbiol Immunol. 2013 Feb;202(1):1-10. doi: 10.1007/s00430-012-0253-2. Epub 2012 Jul 8. Review.

25.

A Toll/interleukin (IL)-1 receptor domain protein from Yersinia pestis interacts with mammalian IL-1/Toll-like receptor pathways but does not play a central role in the virulence of Y. pestis in a mouse model of bubonic plague.

Spear AM, Rana RR, Jenner DC, Flick-Smith HC, Oyston PCF, Simpson P, Matthews SJ, Byrne B, Atkins HS.

Microbiology. 2012 Jun;158(Pt 6):1593-1606. doi: 10.1099/mic.0.055012-0. Epub 2012 Mar 8.

PMID:
22403187
26.

Design and characterization of novel hybrid antimicrobial peptides based on cecropin A, LL-37 and magainin II.

Fox MA, Thwaite JE, Ulaeto DO, Atkins TP, Atkins HS.

Peptides. 2012 Feb;33(2):197-205. doi: 10.1016/j.peptides.2012.01.013. Epub 2012 Jan 24.

PMID:
22289499
27.

Neutrophils are the predominant cell-type to associate with Burkholderia pseudomallei in a BALB/c mouse model of respiratory melioidosis.

Laws TR, Smither SJ, Lukaszewski RA, Atkins HS.

Microb Pathog. 2011 Dec;51(6):471-5. doi: 10.1016/j.micpath.2011.07.002. Epub 2011 Jul 20.

PMID:
21798336
28.

Potent antimicrobial peptides with selectivity for Bacillus anthracis over human erythrocytes.

Dawson RM, Fox MA, Atkins HS, Liu CQ.

Int J Antimicrob Agents. 2011 Sep;38(3):237-42. doi: 10.1016/j.ijantimicag.2011.05.006. Epub 2011 Jul 8.

PMID:
21741801
29.

Antimicrobials for bacterial bioterrorism agents.

Sarkar-Tyson M, Atkins HS.

Future Microbiol. 2011 Jun;6(6):667-76. doi: 10.2217/fmb.11.50. Review.

PMID:
21707313
30.

Yersinia pestis TIR-domain protein forms dimers that interact with the human adaptor protein MyD88.

Rana RR, Simpson P, Zhang M, Jennions M, Ukegbu C, Spear AM, Alguel Y, Matthews SJ, Atkins HS, Byrne B.

Microb Pathog. 2011 Sep;51(3):89-95. doi: 10.1016/j.micpath.2011.05.004. Epub 2011 May 27.

31.

Inhibition of Francisella tularensis LVS infection of macrophages results in a reduced inflammatory response: evaluation of a therapeutic strategy for intracellular bacteria.

D'Elia R, Jenner DC, Laws TR, Stokes MG, Jackson MC, Essex-Lopresti AE, Atkins HS.

FEMS Immunol Med Microbiol. 2011 Aug;62(3):348-61. doi: 10.1111/j.1574-695X.2011.00817.x. Epub 2011 Jun 16.

32.

CD4+ T-cell immunity to the Burkholderia pseudomallei ABC transporter LolC in melioidosis.

Chu KK, Tippayawat P, Walker NJ, Harding SV, Atkins HS, Maillere B, Bancroft GJ, Lertmemongkolchai G, Altmann DM.

Eur J Immunol. 2011 Jan;41(1):107-15. doi: 10.1002/eji.201040881. Epub 2010 Dec 3.

33.

An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor.

Baillie LW, Huwar TB, Moore S, Mellado-Sanchez G, Rodriguez L, Neeson BN, Flick-Smith HC, Jenner DC, Atkins HS, Ingram RJ, Altmann DM, Nataro JP, Pasetti MF.

Vaccine. 2010 Sep 24;28(41):6740-8. doi: 10.1016/j.vaccine.2010.07.075. Epub 2010 Aug 4.

34.

Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis for experimental murine melioidosis.

Kenny DJ, Sefton AM, Brooks TJ, Laws TR, Simpson AJ, Atkins HS.

Int J Antimicrob Agents. 2010 Jul;36(1):87-9. doi: 10.1016/j.ijantimicag.2010.03.019. Epub 2010 May 11.

PMID:
20462743
35.

Towards a Brucella vaccine for humans.

Perkins SD, Smither SJ, Atkins HS.

FEMS Microbiol Rev. 2010 May;34(3):379-94. doi: 10.1111/j.1574-6976.2010.00211.x. Epub 2010 Jan 19. Review.

36.

ATP-Binding Cassette Systems of Brucella.

Jenner DC, Dassa E, Whatmore AM, Atkins HS.

Comp Funct Genomics. 2009:354649. doi: 10.1155/2009/354649. Epub 2010 Feb 11.

37.

A Yersinia pestis guaBA mutant is attenuated in virulence and provides protection against plague in a mouse model of infection.

Oyston PC, Mellado-Sanchez G, Pasetti MF, Nataro JP, Titball RW, Atkins HS.

Microb Pathog. 2010 May;48(5):191-5. doi: 10.1016/j.micpath.2010.01.005. Epub 2010 Jan 22.

38.

Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis against experimental murine Brucella melitensis infection.

Atkins HS, Spencer S, Brew SD, Jenner DC, Sefton AM, MacMillan AP, Brooks TJ, Simpson AJ.

Int J Antimicrob Agents. 2010 Jul;36(1):66-8. doi: 10.1016/j.ijantimicag.2009.10.003. Epub 2009 Dec 21.

PMID:
20022474
39.

Microbial TIR domains: not necessarily agents of subversion?

Spear AM, Loman NJ, Atkins HS, Pallen MJ.

Trends Microbiol. 2009 Sep;17(9):393-8. doi: 10.1016/j.tim.2009.06.005. Epub 2009 Aug 28.

PMID:
19716705
40.

Efficacy of the quinolones trovafloxacin and grepafloxacin for therapy of experimental tularaemia and plague.

Kenny DJ, Sefton AM, Steward J, Brooks TJ, Simpson AJ, Atkins HS.

Int J Antimicrob Agents. 2009 Nov;34(5):502-3. doi: 10.1016/j.ijantimicag.2009.06.023. Epub 2009 Aug 21. No abstract available.

PMID:
19699615
41.

Efficacy of moxifloxacin or gatifloxacin as prophylaxis against experimental murine Brucella melitensis infection.

Atkins HS, Spencer S, Brew SD, Laws TR, Thirlwall RE, MacMillan AP, Brooks TJ, Simpson AJ.

Int J Antimicrob Agents. 2009 Nov;34(5):471-3. doi: 10.1016/j.ijantimicag.2009.06.018. Epub 2009 Aug 13.

PMID:
19682862
42.

The cationic peptide magainin II is antimicrobial for Burkholderia cepacia-complex strains.

Thwaite JE, Humphrey S, Fox MA, Savage VL, Laws TR, Ulaeto DO, Titball RW, Atkins HS.

J Med Microbiol. 2009 Jul;58(Pt 7):923-9. doi: 10.1099/jmm.0.008128-0. Epub 2009 Jun 5.

PMID:
19502364
43.

Efficacy of ciprofloxacin versus doxycycline as prophylaxis against experimental murine Brucella melitensis infection.

Atkins HS, Spencer S, Brew SD, Jenner DC, Russell P, MacMillan AP, Eley SM, Simpson AJ.

Int J Antimicrob Agents. 2009 Nov;34(5):474-6. doi: 10.1016/j.ijantimicag.2009.04.006. Epub 2009 Jun 4.

PMID:
19500948
44.

Enhanced vaccine antigen delivery by Salmonella using antibiotic-free operator-repressor titration-based plasmid stabilisation compared to chromosomal integration.

Leckenby MW, Spear AM, Neeson BN, Williamson ED, Cranenburgh RM, Atkins HS.

Microb Pathog. 2009 Apr;46(4):201-6. doi: 10.1016/j.micpath.2009.01.001. Epub 2009 Jan 24.

PMID:
19490834
45.

Small protective fragments of the Yersinia pestis V antigen.

Vernazza C, Lingard B, Flick-Smith HC, Baillie LW, Hill J, Atkins HS.

Vaccine. 2009 May 11;27(21):2775-80. doi: 10.1016/j.vaccine.2009.03.011. Epub 2009 Mar 13.

PMID:
19366573
46.

Phenotypic and functional characterization of human memory T cell responses to Burkholderia pseudomallei.

Tippayawat P, Saenwongsa W, Mahawantung J, Suwannasaen D, Chetchotisakd P, Limmathurotsakul D, Peacock SJ, Felgner PL, Atkins HS, Titball RW, Bancroft GJ, Lertmemongkolchai G.

PLoS Negl Trop Dis. 2009;3(4):e407. doi: 10.1371/journal.pntd.0000407. Epub 2009 Apr 7.

47.

Development and characterization of mouse models of infection with aerosolized Brucella melitensis and Brucella suis.

Smither SJ, Perkins SD, Davies C, Stagg AJ, Nelson M, Atkins HS.

Clin Vaccine Immunol. 2009 May;16(5):779-83. doi: 10.1128/CVI.00029-09. Epub 2009 Mar 25.

48.

Differential cell surface properties of vegetative Bacillus.

Thwaite JE, Laws TR, Atkins TP, Atkins HS.

Lett Appl Microbiol. 2009 Mar;48(3):373-8. doi: 10.1111/j.1472-765X.2008.02543.x. Epub 2009 Feb 2.

49.

Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy.

Baillie LW, Rodriguez AL, Moore S, Atkins HS, Feng C, Nataro JP, Pasetti MF.

Vaccine. 2008 Nov 11;26(48):6083-91. doi: 10.1016/j.vaccine.2008.09.010. Epub 2008 Sep 19.

50.

Structures of OppA and PstS from Yersinia pestis indicate variability of interactions with transmembrane domains.

Tanabe M, Mirza O, Bertrand T, Atkins HS, Titball RW, Iwata S, Brown KA, Byrne B.

Acta Crystallogr D Biol Crystallogr. 2007 Nov;63(Pt 11):1185-93. Epub 2007 Oct 17.

PMID:
18007034

Supplemental Content

Loading ...
Support Center